Clinical Trial Update: Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for a recombinant human serum albumin/G-CSF fusion protein in breast cancer patients undergoing chemotherapy, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Neutropenia

Drugs mentioned

• Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein (recombinant human serum albumin–granulocyte colony-stimulating factor fusion protein)

Snippet

Sponsor: Tianjin SinoBiotech Ltd. | Conditions: Chemotherapy-induced Neutropenia | Phase 2 | Status: COMPLETED